CJC-1295 with DAC
Product Name: CJC-1295 with DAC (Drug Affinity Complex)
Form: Lyophilised peptide powder (vial)
Typical Strengths: 2 mg – 5 mg per vial
Category: Synthetic peptide / Long-acting Growth Hormone-Releasing Hormone (GHRH) analog
Intended Use: Research peptide for laboratory and experimental studies (not approved for therapeutic or human clinical use)
Overview:
CJC-1295 with DAC is a synthetic analog of the body’s growth hormone-releasing hormone (GHRH) engineered to stimulate the release of endogenous growth hormone (GH) from the anterior pituitary gland. The inclusion of a Drug Affinity Complex (DAC) moiety allows the peptide to bind to albumin in the bloodstream, significantly prolonging its half-life and sustaining its activity compared with the non-DAC form of CJC-1295.
How It Works:
Mimics the natural hypothalamic GHRH signal to activate GHRH receptors on pituitary cells.
The DAC modification extends circulation time (often ~6–8 days in research observations), resulting in longer-lasting stimulation of GH release and downstream IGF-1 increases.
Unlike short-acting peptides that produce quick pulses, the DAC version supports sustained GH exposure over several days.
Key Research Features:
Increased GH and IGF-1 levels following administration, with prolonged biological activity.
Designed for repeated subcutaneous administration in research protocols.
Often studied for effects on metabolic processes influenced by the GH/IGF-1 axis.
Typical Handling & Use:
Supplied as a dry, lyophilised powder requiring reconstitution with sterile diluent prior to use in laboratory settings.
Intended for research purposes only — not for human therapeutic use or self-administration.
Storage and handling should follow appropriate peptide laboratory safety protocols.
Research Observations (from scientific studies):
CJC-1295 with DAC has been shown to sustain increased growth hormone levels for multiple days per dose.
Prolonged elevation of IGF-1 has been observed in repeated dosing studies.
Reviews
There are no reviews yet.